Kilian Kleemann,Neta Rosenzweig,Zhuoran Yin,Xiaoming Zhang,Wesley Nogueira Brandão,Milica A. Margeta,Caitlin M. Schroeder,Sebastian Silveira,Christian Gauthier,Dania Mallah,Kristen M. Pitts,Shawn Herron,H. H. Shorey,Michael Aronchik,Chao Wang,Nimansha Jain,Xiaoyong Bao,Nieske Brouwer,Caroline Baufeld,Susanne Krasemann,Bart J. L. Eggen,Clary B. Clish,Rudolph E. Tanzi,Charlotte Madore,S. H. Wakelin,Jongeun Rhee,Yiran Cheng,John C. Barry,Anthony Yung,Emma Gerrits,Amy Deik,Daniel G. Tenen,Nicolás Santander,Tsuneya Ikezu,Gabriel L. McKinsey,Dean Sheppard,Thomas D. Arnold,Ana Durao,David M. Holtzman,Oleg Butovsky

Abstract:Background APOE4 is the major genetic risk factor for late‐onset Alzheimer Disease (AD). APOE signaling is critical for the transition of homeostatic microglia to the neurodegenerative phenotype (MGnD). The intrinsic role of APOE4 in microglia and its contribution to AD is unclear. Method Generation of Cx3cr1‐CRE ERT2 mice crossed to APOE‐KI(APOE3 and APOE4) fl/fl injected with labeled apoptotic neurons (MGnD‐Pardigm) on WT or APP/PS1 background. Microglia and astrocytes were isolated and sequenced using either bulk RNA‐seq (MGnD‐Paradigm) or single‐cell RNA‐seq (APP/PS1). Crosstalk between cells was determined using the NichenetR database and validated using 1) Recombinant Lgals3 intracranial injection into APP/PS1 mice and 2) Adoptive transfer of microglia, from APOE3‐KI, APOE4‐KI and APOE4‐cKO mice challenged with labeled apoptotic neurons, into WT mice and isolation of astrocytes. Result Expression of APOE4 in microglia impaired MGnD‐transition in response to neurodegeneration and in APP/PS1 mice. Conditional deletion of APOE4 in microglia restored MGnD phenotype and reduced plaque pathology. Furthermore, increased astrocytic recruitment towards plaques and their activation by increased Gfap and Serpina3n expression was identified. Microglial Lgals3 was determined as critical crosstalk effector to promote astrocyte response to plaque pathology and acute neurodegeneration. AD female APOE4 carriers showed impaired induction of MGnD signature genes and astrocyte activation, including LGALS3 and GFAP respectively, supporting a conserved disease mechanism in a sex‐dependent manner. Conclusion APOE4 impairs MGnD‐microglia in AD and prevents their crosstalk with astrocytes. Lgals3 is identified as important positive regulator for microglia–astrocyte crosstalk in response to AD pathology and provides a potential therapeutic target for treatment of AD.

Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

Alzheimer’s disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGF-mediated checkpoints

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints

AD-linked R47H- TREM2 mutation induces disease-enhancing proinflammatory microglial states in mice and humans

APOE4 Impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia

AD-linked R47H-<i>TREM2</i>mutation induces disease-enhancing proinflammatory microglial states in mice and humans

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

Human Glia‐specific Functional Dysregulations Affected by APOE Ε4 Risk of Alzheimer's Disease

Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience

Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease

Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease

Cell-autonomous Effects of APOE4 in Restricting Microglial Response in Brain Homeostasis and Alzheimer’s Disease

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology

Non-coding Variability at the APOE Locus Contributes to the Alzheimer’s Risk

The Alzheimers Disease Risk Genes MS4A4A And MS4A6A Cooperate to Negatively Regulate Trem2 and Microglia states